When Ambition Meets Ambiguity: The Trends and Sentiments Shaping Biotech in 2026
ICON Biotech’s 2025 survey of 163 global biotech leaders, plus 100 Chinese executives, reveals shifting dynamics as China overtakes the United States in innovative trial volume and is projected to contribute 35% of FDA approvals by 2040. Funding remains scarce, with NIH cuts of nearly 40% and capital increasingly concentrated in a few large rounds, yet 75% of respondents plan to boost R&D spending. The modality landscape has moved away from small molecules toward cell therapy, antibody‑drug conjugates and microbiome approaches, while neurology now eclipses oncology as the most active therapeutic focus. Geopolitical uncertainty and talent shortages, especially in APAC, are cited as growing operational challenges.
Pharmaceutical Executive Daily: FDA Expands Approval of Leucovorin
The FDA has expanded approval of leucovorin calcium tablets as the first therapy for cerebral folate transport deficiency linked to FOLR1 gene variants. The decision relied on published case literature, showing 87‑89% of patients achieved clinical improvement. In oncology, AstraZeneca...
How FDA's Removal of the Two-Trial Requirement Affects Development Programs
The FDA has eliminated the longstanding requirement for two pivotal clinical trials, adopting a single‑trial default to speed drug approvals. The agency pairs this change with a mandate for more rigorous post‑market surveillance to catch safety signals after launch. Pharmaceutical...
AI Has Redefined Healthcare Communication — and There’s No Opting Out
Conversational AI tools such as ChatGPT Health and Claude for Healthcare are reshaping how patients and clinicians obtain medical information. OpenAI reports that over 5% of global ChatGPT interactions—about 40 million daily users—are health‑related, while 40% of U.S. healthcare workers use...
Pharmaceutical Executive Daily: Vinay Prasad Set to Leave CBER for Second Time
Vinay Prasad has left the FDA’s Center for Biologics Evaluation and Research (CBER) for the second time in under a year, signaling a notable leadership turnover at a key regulatory hub for biologics, vaccines and gene therapies. In parallel, GlaxoSmithKline...
The Impact of a CRM Transition: Q&A with David Rosner
Pharma firms must choose between Veeva and Salesforce CRMs after the vendors split, creating a roughly even market split among the top 20 life‑science companies. Deloitte’s David Rosner says the decision is more than a tech upgrade; it can reshape...
Key Factors Contributing to Uncertainty in Moderna's mRNA Vaccine Review
The FDA initially refused to review Moderna’s mRNA‑based flu vaccine, prompting surprise among industry observers. After a White House meeting, the agency reversed course and granted Moderna a Type A meeting, effectively resetting the review process. Lanton notes this regulatory flip‑flop...
From Approval to Access: 4 Steps to Rethinking Market Access Strategy in Specialty Pharma
The article outlines a four‑step framework for specialty pharma companies to redesign market‑access strategies as they move from approval to commercial launch. It stresses securing payer formulary placement, deploying a focused sales force, establishing a trusted pharmacy network, and centering...
Consent‑Driven Targeting: Building Trust With Patients and HCPs
Life‑science marketers face mounting pressure to deliver personalized content while meeting stricter privacy regulations such as CCPA and the EU Data Act. Companies are shifting from static consent checkboxes to unified, real‑time consent frameworks that synchronize preferences across CRM, CDP,...
Pharmaceutical Executive Daily: Cognito Therapeutics and Nexcure Secure Financing Rounds
Cognito Therapeutics closed an oversubscribed $105 million Series C round to fast‑track its neurodegenerative programs, while Nexcure raised $19 million in a Series A to fund its immunology pipeline. At the same time, artificial‑intelligence advances—particularly large language models—are reshaping pharmacovigilance by automating analysis of...
Pharma Funding Roundup: Cognito Therapeutics Closes Oversubscribed $105 Million Series C Financing, Nexcure Launches $19 Million Series A Financing
Cognito Therapeutics closed an oversubscribed $105 million Series C round to fund its at‑home Alzheimer’s stimulation device, Spectris, targeting a 2027 market launch after a pivotal readout. NexCure raised $19 million in a Series A to build an outpatient platform that standardizes and expands...
The Ongoing Impact of MFN Pricing
The pharmaceutical industry is grappling with evolving Most‑Favored‑Nation (MFN) pricing rules as the TrumpRx initiative clarifies administration expectations. Recent Supreme Court rulings on IEEPA tariffs, distinct from Section 232 tariffs used in MFN negotiations, add uncertainty to pricing strategies. Manufacturers must...
Pharmaceutical Executive Daily: Pharma Industry's AI Adoption
Pharmaceutical companies are striking major deals while accelerating AI integration. Antengene and UCB signed a global licensing agreement worth roughly $1 billion to develop a bispecific T‑cell engager for cancer therapy. Teva Pharmaceutical Industries secured a $400 million strategic growth capital partnership...
Antengene and UCB Enter $1.18 Billion Global License Agreement for Bispecific T-Cell Engager
Antengene and UCB have signed a global license agreement to develop ATG‑201, a CD19/CD3 bispecific T‑cell engager targeting B‑cell‑driven autoimmune diseases. The deal delivers an $80 million upfront payment and unlocks more than $1.1 billion in development and commercial milestones, plus tiered...
Teva and Blackstone Life Sciences Enter $400 Million Strategic Growth Capital Agreement
Teva Pharmaceuticals has secured a $400 million strategic growth capital agreement with Blackstone Life Sciences to fund the Phase III development of duvakitug, a TL1A‑targeting monoclonal antibody for ulcerative colitis and Crohn’s disease. The four‑year deal grants Blackstone milestone payments and low‑single‑digit...
FDA's History with Complex Plants
The FDA issued its first botanical drug guidance in 2004 and updated it in 2016, yet only four complex plant‑derived drugs have been approved to date. Ajna Biosciences, led by Joel Stanley, has secured clearance to begin a Phase 2 trial...
Enhancing Cold Chain Visibility
SpotSee introduced WarmMark QR, a battery‑free, QR‑enabled temperature sensor designed for cold‑chain logistics. The device delivers affordable, real‑time, package‑level temperature data, replacing error‑prone visual indicators. By allowing remote data access, it improves recipient adoption and streamlines monitoring for shippers. The...
Pharmaceutical Executive Daily: Novo Nordisk Commits $506 Million to Ireland Manufacturing Site
Novo Nordisk announced a $506 million investment to expand its manufacturing site in Ireland, aiming to boost capacity for diabetes and obesity therapies. The expansion addresses rising global demand and enhances supply‑chain resilience. The announcement coincides with industry focus on measuring...
Patent Term Extension: Challenges with Defining and Claiming Approved Biologics
Patent term extension (PTE) offers up to five extra years of exclusivity for FDA‑approved drugs, but biologics present a unique hurdle because the law hinges on defining the “active ingredient.” Unlike small molecules, biologics are large, variable structures, making it...
Real-World Data Brings New Insights to Natural History of Disease Studies
Real‑world data (RWD) is reshaping natural history studies by delivering longitudinal, patient‑level information that was previously only obtainable through costly prospective trials. Advances in artificial intelligence and natural language processing now allow rapid extraction of structured data from unstructured sources...
Pharmaceutical Executive Daily: FDA Approves Hernexeos
The FDA approved Hernexeos through the national priority voucher program, a mechanism that fast‑tracks drugs addressing unmet medical needs. Industry leaders are evaluating direct‑to‑consumer (DTC) models to broaden access to HIV prevention tools, leveraging digital and telehealth channels. Additionally, the...
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
Gilead’s U.S. HIV prevention VP Ashley Gildea unveiled a direct‑to‑consumer campaign for Yeztugo, the first twice‑yearly injectable PrEP. The campaign, anchored by a music‑driven “One2PrEP” spot, aims to lift awareness among the estimated 2.2 million Americans who could benefit from PrEP...
Pharma Leadership Roundup: Sarepta Therapeutics CEO Announces Retirement, Rivus Pharmaceuticals Appoints New CEO
Sarepta Therapeutics announced that CEO Douglas Ingram will retire by the end of 2026, triggering a formal succession search. The move follows a turbulent 2025 in which the company’s flagship gene therapy Elevidys was linked to two patient deaths, prompting...
What Does the Rollout of Trump Rx Reveal?
Buzz Health President Joseph Kleiman says TrumpRx is advancing drug‑price transparency by giving consumers early visibility into prescription costs. He notes that real‑time pricing can help patients compare options but also warns that prices are dynamic and may change before...
Leading in the Psychedelic Space: Q&A with Tarek Rabah
Otsuka America became the first major pharmaceutical company to back psychedelic‑inspired medicines in 2020 through a partnership with COMPASS Pathways, and deepened that commitment by acquiring Mindset in 2023. The company is applying its long‑standing CNS expertise to develop serotonergic...
Pharmaceutical Executive Daily: FDA Approves Braftovi
The FDA has approved Braftovi for patients with BRAF V600E‑mutant metastatic colorectal cancer, expanding targeted options in a genetically defined subset. The clearance underscores the momentum of biomarker‑driven oncology and combination‑therapy strategies. In parallel, Novo Nordisk announced a $2 billion partnership with Vivtex...
Medicines and Healthcare Products Regulatory Agency Confiscates 2,000 Doses of Illegal Weight-Loss Drugs: Report
Britain's Medicines and Healthcare products Regulatory Agency (MHRA) seized nearly 2,000 doses of illegal weight‑loss drugs in raids on sites in Lincolnshire and Nottinghamshire, marking its second major operation in four months. The confiscated products were labelled as containing tirzepatide...
FDA Enforcement on Copycat GLP-1's Could Reshape Retail Pharmacy Economics: Q&A with David Graziano
The FDA’s crackdown on non‑approved or “copycat” GLP‑1 drugs is expected to push patients toward FDA‑approved therapies, elevating the role of retail pharmacies as primary access points. GoodRx’s head of retail network, David Graziano, says the company’s cost‑plus pricing model...
Pharmaceutical Executive Daily: Novo Nordisk Announces Price Reductions for GLP-1 Products
Novo Nordisk announced steep price cuts for its GLP‑1 diabetes and obesity drugs, aiming to broaden patient access amid intensifying pricing scrutiny. AbbVie is committing $380 million to expand API manufacturing capacity, reinforcing supply‑chain resilience. Bora Pharmaceuticals and GSK sealed a...
The Effectiveness of TV Advertising for Pharma
Pharma TV advertising is encountering stricter regulatory limits, especially since the Trump administration tightened rules around black‑box warnings and ad volume. While TV still reaches broad audiences, its effectiveness is waning as digital platforms enable far more precise, N‑of‑1 targeting....
Revealing the Structural Fingerprints of Disease: Q&A with Faraz Choudhury
Immuto’s CEO Faraz Choudhury explains that conventional target discovery, which focuses on gene mutations and protein abundance, overlooks disease‑specific protein conformations. The company’s platform maps surface protein conformations (SPCs) in living, patient‑derived models using high‑resolution mass spectrometry and AI‑driven analysis,...
Merck’s Oncology Spin-Out: Organizational Design as Patent Cliff Strategy
Merck has created a standalone oncology business unit to confront the concentration risk posed by Keytruda, which now generates over half of its pharmaceutical sales and faces patent expiry around 2028. The restructuring treats organizational design as a strategic lever...
How FDA's Action Against Non-FDA-Approved GLP-1 Products Affects the Competitive Landscape
Jay Bregman, CEO of Andel, says the FDA’s pending crackdown on non‑FDA‑approved GLP‑1 compounds is long overdue and will target the burgeoning market of compounded semaglutide. He estimates roughly 1.5 million patients currently rely on these unapproved products, a figure he...
The Pulse of Pharma Change in 2026
In a February 20, 2026 Pharm Exec Podcast, ZS CEO Pratap Khedkar, PhD, outlined three converging trends reshaping pharma: heightened AI integration, evolving ecosystem partnerships, and sweeping US‑driven policy reforms. Drawing on his nine‑year tenure leading ZS’s global pharmaceuticals practice and its advanced data‑science...
Pharmaceutical Executive Daily: FDA Plans to Remove Two Study Requirement for New Drug Approvals
The FDA announced it will drop the historic requirement for two adequate and well‑controlled studies in certain new‑drug approval pathways, a move that could accelerate timelines and lower development costs. The change is especially relevant for therapies targeting unmet medical...
ACIP February Meeting Cancelled: Report
The Advisory Committee on Immunization Practices (ACIP) cancelled its scheduled February 25‑27, 2026 meeting, and no new date has been announced. The cancellation occurs amid a wave of senior HHS leadership changes, including the departure of Deputy Secretary Jim O’Neill and General...
Eli Lilly Announces Positive Results for Treating Crohn’s Disease with Omvoh
Eli Lilly reported that its biologic Omvoh (mirikizumab) sustained steroid‑free remission for three years in Crohn’s disease patients in the Phase 3 VIVID‑2 open‑label extension study. More than 90% of participants remained in remission, with 80% experiencing relief from bowel urgency. The...
